Aclaris Therapeutics (ACRS) Projected to Post Quarterly Earnings on Tuesday

Aclaris Therapeutics (NASDAQ:ACRS) is anticipated to issue its quarterly earnings data before the market opens on Tuesday, February 25th. Analysts expect the company to announce earnings of ($0.09) per share and revenue of $7.04 million for the quarter.

Aclaris Therapeutics Price Performance

Aclaris Therapeutics stock opened at $2.25 on Friday. The company’s 50 day simple moving average is $2.54 and its 200 day simple moving average is $2.12. Aclaris Therapeutics has a fifty-two week low of $0.95 and a fifty-two week high of $5.17. The firm has a market capitalization of $160.36 million, a price-to-earnings ratio of -4.32 and a beta of 0.50.

Analysts Set New Price Targets

A number of brokerages have weighed in on ACRS. BTIG Research raised shares of Aclaris Therapeutics from a “neutral” rating to a “buy” rating and set a $8.00 price target on the stock in a research note on Tuesday, November 19th. Piper Sandler upgraded shares of Aclaris Therapeutics from a “neutral” rating to an “overweight” rating and lifted their price objective for the company from $3.00 to $13.00 in a report on Monday, November 18th. StockNews.com downgraded shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, February 8th. Cantor Fitzgerald upgraded shares of Aclaris Therapeutics to a “strong-buy” rating in a report on Thursday, January 30th. Finally, Jefferies Financial Group upgraded shares of Aclaris Therapeutics from a “hold” rating to a “buy” rating and lifted their price objective for the company from $2.00 to $7.00 in a report on Tuesday, November 19th. One research analyst has rated the stock with a sell rating, five have assigned a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $11.00.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.